Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06116253 · ClinicalTrials.gov registry record · NA
Advanced Diffusion Imaging in Renal Cancer Patients
A NA study of Renal Cancer, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT06116253 is a NA study of Renal Cancer that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 90 participants, below the 607-participant average among 29 other Renal Cancer trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06116253, a NA study of Renal Cancer, is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to apply advanced diffusion imaging in a two-pronged assessment of renal mass patients: (1) characterization of lesion malignancy and subtype, and (2) prediction of renal function stability or decline following partial nephrectomy.
Conditions Studied
Interventions
- DEVICE Magnetic Resonance Imaging (MRI) Scan
- DRUG Tc-99m Pentetate
Study Locations (1)
New York
- NYU Langone Health - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-12-01 |
| Est. Completion | 2028-12-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06116253
The ClinicalTrials.gov registry entry for NCT06116253 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 607-participant average among 29 other Renal Cancer trials with a reported enrollment target (85% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cancer appearing as the primary indexed condition, and to 2 interventions - of which Magnetic Resonance Imaging (MRI) Scan is the first listed.
NCT06116253 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06116253 about?
NCT06116253 is a clinical study titled "Advanced Diffusion Imaging in Renal Cancer Patients". The objective of this study is to apply advanced diffusion imaging in a two-pronged assessment of renal mass patients: (1) characterization of lesion malignancy and subtype, and (2) prediction of renal function stability or decline following partial nephrectomy.
What is the current status of trial NCT06116253?
This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2022-12-01. Estimated completion is 2028-12-01.
What conditions does trial NCT06116253 study?
This clinical trial studies the following conditions: Renal Cancer.
What interventions are being tested in trial NCT06116253?
The interventions under investigation include: Magnetic Resonance Imaging (MRI) Scan (DEVICE), Tc-99m Pentetate (DRUG).
Who is sponsoring clinical trial NCT06116253?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06116253 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Video Education With Result Dependent dIsclosure
RECRUITING · NA
-
Decision Aid (DA) for Renal Patients
RECRUITING · NA
-
Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
ACTIVE NOT RECRUITING · NA
-
The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)
ACTIVE NOT RECRUITING · NA
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.